View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Bankinter S.A.: 1 director

A director at Bankinter S.A. sold 2,000 shares at 13.030EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

 PRESS RELEASE

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares - July 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry unde...

 PRESS RELEASE

Sanofi: Informations relatives au nombre de droits de vote et d'action...

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions...

 PRESS RELEASE

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the ...

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases Paris, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, ...

 PRESS RELEASE

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignati...

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Données de l’étude positive de phase 2 évaluant le rilzabrutinib pour le traitement de la maladie liée aux IgG4 présentée à l’EULAR de 2025Cette nouvelle désignation de médicament orphelin souligne l’engagement de Sanofi en faveur du développement de nouveaux médicaments contre les maladies rares à médiation immunitaire Paris, le 14 août 2025. ...

 PRESS RELEASE

Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neurosci...

Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Paris, le 6 août 2025. Sanofi annonce la finalisation de  (« Vigil »). Cette acquisition renforce le pipeline de Sanofi en neurologie avec le VG-3927, un nouvel agoniste oral de TREM2, qui sera évalué dans une étude clinique de phase 2 chez des patients atteints de la maladie d’Alzheimer. En outre, l’acquisition du pipeline préclinique de Vigil renforcera la recherche de Sanofi dans diverses maladies neurodégénératives. En juin 2024, Sanofi a réalisé u...

 PRESS RELEASE

Press Release: Sanofi completes the acquisition of Vigil Neuroscience,...

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc. Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of  (“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer’s disease. In addition, the acquisition of Vigil’s preclinical pipeline will further strengthen Sanofi’s research in various neurodegenerative diseases. In June 2024, Sanofi ...

Research Department
  • Research Department

IBERIAN DAILY 05 AUGUST (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: CELLNEX, NATURGY. Stock markets pause for a break European stock markets recovered after the strong corrections seen last Friday, fuelled by banks. Thus, in the STOXX 600 most sectors (16/20) ended with gains, led by Banks and Insurance vs. Pharma and Retail that were the worst performers. On the macro side, in the euro zone, August’s Sentix dropped significantly as opposed to expectations following the tariff agreement signed with the US to the worst level since April. In the US,...

Steven Gould
  • Steven Gould
Steven Gould
  • Steven Gould
Julian Dobrovolschi ... (+2)
  • Julian Dobrovolschi
  • Steven Boumans
BRE MBANK SA
V1S ARKEMA
LHN HOLCIM AG
LR LEGRAND
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
AC ACCOR SA
ENX EURONEXT NV
VIE VEOLIA ENVIRONNEMENT SA
SGO COMPAGNIE DE SAINT-GOBAIN SA
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
DG VINCI SA
SU SCHNEIDER ELECTRIC SE
RNO RENAULT SA
ADS ADIDAS AG
APAML APERAM SA
LI KLEPIERRE SA
COV COVIVIO SA
OUT1V OUTOKUMPU OYJ
GFC GECINA SA
NXI NEXITY SA CLASS A
FLY SOCIETE FONCIERE LYONNAISE SA
EN BOUYGUES SA
GYC GRAND CITY PROPERTIES SA
MERY MERCIALYS SA
GLE SOCIETE GENERALE S.A. CLASS A
INEA FONCIERE INEA
WHA WERELDHAVE N.V.
TEP TELEPERFORMANCE SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
BLND BRITISH LAND COMPANY PLC
ITRK INTERTEK GROUP PLC
KOF KAUFMAN & BROAD SA
ALTA ALTAREA SCA
VNA VONOVIA SE
ACX ACERINOX SA
XIOR XIOR STUDENT HOUSING N.V.
SAF SAFRAN S.A.
BCP BANCO COMERCIAL PORTUGUES S.A.
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
ENEL ENEL SPA
ICAD ICADE SA
BYG BIG YELLOW GROUP PLC
COFB COFINIMMO SA
NEM NEMETSCHEK SE
CAI CA IMMOBILIEN ANLAGEN AG
TEG TAG IMMOBILIEN AG
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
VASTB VASTNED RETAIL BELGIUM NV
PSPN PSP SWISS PROPERTY AG
UBS UBM DEVELOPMENT AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
AMS AMADEUS IT GROUP SA CLASS A
CARM CARMILA SAS
EVK EVONIK INDUSTRIES AG
LEG LEG IMMOBILIEN AG
CPINV CARE PROPERTY INVEST SA
SAFE SAFESTORE HOLDINGS PLC
ANDR ANDRITZ AG
ARG ARGAN SA
VGP VGP NV
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
WLN WORLDLINE SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
CLNX CELLNEX TELECOM S.A.
RACE FERRARI NV
DKG DEUTSCHE KONSUM REIT-AG
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
PIRC PIRELLI & C. S.P.A.
REY REPLY S.P.A.
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
NSI NSI N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
AEDAS AEDAS HOMES SA
KBX KNORR-BREMSE AG
NEXI NEXI S.P.A.
CPR DAVIDE CAMPARI-MILANO N.V.
WDP WAREHOUSES DE PAUW SCA
UMG UNIVERSAL MUSIC GROUP NV
ECMPA EUROCOMMERCIAL PROPERTIES NV
DTG DAIMLER TRUCK
CTPNV CTP NV
ONE ONE UNITED PROPERTIES SA
SHUR SHURGARD SELF STORAGE LIMITED
TEN TENARIS S.A.
Andres Bolumburu
  • Andres Bolumburu

CELLNEX: 1H’25 RESULTS (ANÁLISIS BANCO SABADELL)

2Q'25 vs. 2Q'24 Results Sales: € 978.0 M (+0.3% vs. +0.2% BS(e) and +0.4% consensus); EBITDA: € 807.0 M (+0.9% vs. +0.9% BS(e) and +1.0% consensus); Net Profit: € -66.0 M (€ -379.0 M in 1H'24); 1H'25 vs. 1H'24 Results Sales: € 1.942 Bn (+1.1% vs. +1.0% BS(e) and +1.1% consensus); EBITDA: € 1.605 Bn (+1.7% vs. +1.7% BS(e) and +1.8% consensus); Net Profit: € -115.0 M (€ -418.0 M in 1H'24);

Andres Bolumburu
  • Andres Bolumburu

CELLNEX: RDOS. 1S’25 (ANÁLISIS BANCO SABADELL)

Rdos. 2T'25 vs 2T'24: Ventas: 978,0 M euros (+0,3% vs +0,2% BS(e) y +0,4% consenso); EBITDA: 807,0 M euros (+0,9% vs +0,9% BS(e) y +1,0% consenso); BDI: -66,0 M euros (-379,0 M euros en 1S'24). Rdos. 1S'25 vs 1S'24: Ventas: 1.942 M euros (+1,1% vs +1,0% BS(e) y +1,1% consenso); EBITDA: 1.605 M euros (+1,7% vs +1,7% BS(e) y +1,8% consenso); BDI: -115,0 M euros (-418,0 M euros en 1S'24).

Research Department
  • Research Department

IBERIAN DAILY 01 AUGUST (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: CELLNEX, IBERDROLA, REDEIA, SANTANDER. Trade matters put Europe in the red once again European stock markets fell due to trade matters. After the 01 August deadline passed, a 35% tariff was placed on Canada, 50% on Brazil, 25% on India, 20% on Taiwan and 39% on Switzerland, with another 69 trade partners facing tariffs between 10-41% if new agreements are not reached. As for Mexico, the country will continue to have a 25% tariff due to fentanyl, 25% on automobiles and 50% on steel...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch